Treatment of Antiphospholipid Antibody Syndrome—Reply
- 5 July 2006
- journal article
- letter
- Published by American Medical Association (AMA)
- Vol. 296 (1) , 42-43
- https://doi.org/10.1001/jama.296.1.43-a
Abstract
In Reply: We agree with Drs Wahl and Regnault that outcome data from patients with a single positive antiphospholipid antibody test may not be generalizable to patients with definite APS, as defined by the Sapporo criteria1 or more recently proposed amendments to these criteria.2 We address this issue in our review and qualify our recommendations for the use of aspirin or warfarin in the treatment of stroke to indicate that they apply to “patients with a first ischemic stroke and a single positive antiphospholipid antibody test result . . . ,” reflecting the design of the Antiphospholipid Antibodies and Stroke Study.3 No randomized trials have evaluated different antithrombotic treatments in patients with stroke in whom APS was diagnosed according to the Sapporo criteria.Keywords
This publication has 3 references indexed in Scilit:
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic StrokeJAMA, 2004
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999